The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech (I)
The impact of sleep disturbances (SD) on quality of life, psychological morbidity, and survival of advanced cancer patients (ACP) and caregivers (CG).
 
Fay J. Hlubocky
No Relationships to Disclose
 
Tamara Sher
No Relationships to Disclose
 
David Cella
Stock and Other Ownership Interests - FACIT.org
Consulting or Advisory Role - Abbvie; Bayer; GlaxoSmithKline; Pfizer
Research Funding - Bayer (Inst); Genentech (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; GlaxoSmithKline
 
Bonnie J. Yap
No Relationships to Disclose
 
Mark J. Ratain
Stock and Other Ownership Interests - Biscayne Pharmaceuticals; PrescriptIQ; Venaxis
Consulting or Advisory Role - AbbVie; Amgen; Biomarin; Biscayne Pharmaceuticals; Circle Pharma; Cyclacel; Drais Pharmaceuticals; Genentech/Roche; Portola Pharmaceuticals; Shionogi; Venaxis
Research Funding - Dicerna (Inst); OncoTherapy Science (Inst)
Patents, Royalties, Other Intellectual Property - pending patent related to a genomic prescribing system; pending patent related to a genomic prescribing system (Inst); royalties related to UGT1A1 genotyping for irinotecan; royalties related to UGT1A1 genotyping for irinotecan (Inst)
Expert Testimony - multiple generic companies
 
Jeffery Peppercorn
No Relationships to Disclose
 
Christopher Daugherty
No Relationships to Disclose